Eli Lilly plans to invest $400 million in its manufacturing facilities at its Lilly Technology Center campus in Indianapolis, US. The plans are driven by increasing demand and they provide additional manufacturing capacity for future medicines coming from Lilly's pipeline. These new investments will create approximately 100 new highly skilled jobs at the company.
The investments include enhancements to existing manufacturing facilities that make insulin, additional capacity for its growing portfolio of diabetes medicines and initial capital investments for future medicines.
"These investments demonstrate Lilly's commitment to our manufacturing footprint in Indiana and the US, and have been made possible by the tax reform measures passed by Congress in 2017," said David A. Ricks, Lilly's chairman and CEO. "With more capital available as a result of tax reform, Lilly and other Indiana companies are able to re-invest and expand production here at home. This is crucial for us to continue to advance our state's economy and drive future investment – adding high-tech jobs and facilities that keep Indiana competitive in the global marketplace."
With more capital available as a result of tax reform, Lilly and other Indiana companies are able to re-invest and expand production in the US
"These investments support our manufacturing capabilities in Indianapolis, including additional capacity and technology upgrades to our active ingredient, syringe filling, device assembly and packaging operations," said Myles O'Neill, Senior VP and President of Manufacturing Operations. "All of these projects support Lilly's investment in next-generation manufacturing and feature high levels of automation, robotics, new technologies and advanced data analytics."
O'Neill noted that in addition to increasing the capacity and capabilities needed to provide a safe and reliable supply of medicine for people, the investments also allow Lilly to add highly skilled US manufacturing jobs.
Lilly has invested over $5bn in the US since 2012, with the majority of this investment in its Indiana facilities and nearly $2bn in manufacturing of diabetes medicines.
